The report provides a detailed analysis essential for establishing a Tecovirimat production plant. It encompasses all critical aspects necessary for Tecovirimat production, including the cost of Tecovirimat production, Tecovirimat plant cost, Tecovirimat production costs, and the overall Tecovirimat production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Tecovirimat production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Tecovirimat is an antiviral medication that is used for treating orthopoxvirus infections. It is utilised for managing smallpox, monkeypox, cowpox, and complications from vaccinia virus replication post-smallpox vaccination. It has approval from the FDA for smallpox in adults and children, EMA for smallpox, mpox, and cowpox in those ≥13 kg. It works as first-line therapy under the CDC's expanded access IND for severe mpox cases, especially in high-risk immunocompromised patients (like HIV). Its early administration within the first week of symptoms accelerates lesion resolution, reduces hospitalisation, and improves outcomes in observational studies. It causes mild side effects like headache, nausea, abdominal pain, vomiting, dry mouth, indigestion, muscle pain, etc.
The market for Tecovirimat is driven by growing orthopoxvirus outbreaks like mpox. The extensive government stockpiling for biodefense via US BARDA, DoD contracts, and international orders from Canada, Japan, EMA, and ASEAN contributes to its market growth. The regulatory expansions, like approvals from the FDA and EMA for smallpox/mpox, with limited competition from other options, along with R&D for IV formulations, fuel its market.
The industrial Tecovirimat procurement is driven by government bulk purchases for Strategic National Stockpiles, joint international mechanisms and bioterrorism preparedness. Other factors, like SIGA's monopoly status, along with high costs, raw material shortages, and supply chain vulnerabilities, impact its sourcing.
Raw Material for Tecovirimat Production
According to the Tecovirimat production plant project report, the key raw materials used in the production of Tecovirimat include Maleic Anhydride, 4-(Trifluoromethyl)Benzohydrazide, tert-Butoxyformyl components, and Chiral bifunctional Organocatalyst.
Production Process of Tecovirimat
The extensive Tecovirimat production cost report consists of the following major industrial production process:
- From Maleic Anhydride: Tecovirimat synthesis starts with maleic anhydride reacting via organocatalytic Mumm rearrangement. The reaction takes place under ambient conditions using a chiral bifunctional organocatalyst to stereoselectively form maleimide intermediates. This is followed by Diels-Alder cycloaddition of intermediates with electron-rich dienes to construct the bicyclic core structure. The final acylation with acid chloride or activated carboxylic acid takes place, which leads to the formation of Tecovirimat as the final antiviral agent.
Tecovirimat has the molecular formula of C19H15F3N2O3 and a molecular weight of 376.33 g/mol. It contains a complex tetracyclic structure with a fused cyclopropanoisoindole core, trifluoromethyl-substituted benzamide, and two carbonyl groups. It appears as a white to off-white crystalline solid with limited water solubility but good solubility in organic solvents. It shows moderate plasma protein binding (77-82%), metabolism primarily via UGT1A1/A4 hydrolysis, producing metabolites like M4, M5, and 4-(trifluoromethyl)benzoic acid. It requires storage at -20 degree Celsius for stability. All these physical and chemical properties makes it useful as an antiviral agent.
